RCPA pharmacogenomic clinical indications for three new drugs

The Royal College of Pathologists of Australasia (RCPA) recently completed a review of the RCPA pharmacogenomic clinical indications. The indications were developed in 2024 by a multidisciplinary Advisory Group of prescribers, pathologists, scientists, pharmacists and pharmacologists with expertise in pharmacogenomics, and with feedback from Australian organisations representing healthcare professionals. They are informed by peer-reviewed International and Australian guidelines and approved product labels.

A key role of the Advisory Group is to review the clinical indications annually.  The 2025 review was completed in October 2025. A literature review identified three new drugs; irinotecan, lamotrigine and venlafaxine requiring an in depth review.  These updated guidelines came into effect on 29 October 2025. The next review will be in 2026.

As a stakeholder that endorsed the clinical indications in 2024, the RCPA would be grateful if you could please inform your members of the outcome of the 2025 review.

The RCPA would be happy to address questions and these maybe emailed to the PGx Advisory Group.